ADORA3 and metabolic dysfunction-associated steatohepatitis: A1AR agonists are in clinical trials for the treatment of cardiac arrhythmias and neuropathic pain; A2aAR agonists are in clinical trials for myocardial perfusion imaging and as anti-inflammatory agents; A2bAR agonists are in preclinical evaluation for the potential treatment of cardiac ischemia; and A3AR agonists are in clinical trials for the treatment of psoriasis, NAFLD, with or without nonalcoholic steatohepatitis (NASH), and HCC [31].